Media Release

30 October 2026

Quarterly Shareholder Report | September 2026

Syntara Limited (ASX: SNT), a clinical-stage drug development company, is pleased to provide a summary of its activities for the quarter ended 30 September 2026:

- **Preliminary Phase 2 SNT-4728 results demonstrate a statistically significant reduction in inflammation within a key Parkinson's disease-related brain region.**
- **Additional SNT-4728 results show a statistically significant improvement in clinician-assessed motor signs compared with placebo, 12 weeks after treatment ceased.**
- **AZALOX study advances to the final Phase 1b dose cohort, supporting the potential expansion of amsulostat into myelodysplastic neoplasms.**
- **Subsequent to quarter end, SNT-9465 Phase 1b hypertrophic scar study expanded to 30 participants, with top-line results expected in Q1 2027.**
- **A$4.7 million R&D tax incentive received, providing non-dilutive funding to support the Company's development programs.**

Syntara CEO Gary Phillips said:

"The September quarter delivered encouraging progress across our clinical pipeline. Preliminary results from the SNT-4728 Phase 2 study demonstrated a reduction in neuroinflammation in a brain region central to Parkinson's disease motor symptoms. The additional clinical results reported after quarter end build on these findings, showing an improvement in clinician-assessed motor function compared with placebo that remained evident 12 weeks after treatment ceased. Together, these exploratory findings provide a strong rationale for further evaluation of SNT-4728 in people with iRBD and potentially early Parkinson's disease. We look forward to working with our research collaborators to complete the remaining analyses and assess the next steps for the program.

"The AZALOX study advanced to its final Phase 1b dose cohort and, subsequent to quarter end, announced the expansion of our SNT-9465 skin scarring study to provide a larger safety, tolerability and exploratory activity dataset. With preliminary AZALOX data and SNT-9465 top-line results, we have important clinical milestones to look forward to."

CLINICAL TRIAL UPDATES

Amsulostat

AZALOX MDS Study Advances to Final Phase 1b Dose Cohort
Syntara announced completion of the first dose-escalation cohort in the Phase 1b component of the AZALOX clinical trial evaluating amsulostat in combination with the hypomethylating agent 5-Azacitidine (5-AZA) in patients with high-risk myelodysplastic neoplasms (MDS) and chronic myelomonocytic leukaemia (CMML).

The initial cohort evaluated amsulostat at 150 mg twice daily in combination with 5-AZA. No dose-limiting toxicities were observed and no new adverse events attributable to amsulostat were reported. Following review of these safety data, the independent Drug Safety Monitoring Board approved escalation to the final Phase 1b dose cohort, evaluating amsulostat at 200 mg twice daily.

The Phase 1b component is intended to establish the safety profile and recommended Phase 2 dose of amsulostat in combination with 5-AZA. Subject to completion of the final dose cohort and review of the associated safety data, the study is expected to progress to a Phase 2 component evaluating the selected dose in approximately 30 patients.

AZALOX is being conducted through the German MDS Study Group under the sponsorship of Heidelberg University, in collaboration with the Coordination Centre for Clinical Studies Heidelberg, with financial support from German Cancer Aid and includes 10 German clinical trial sites.

The study follows encouraging preclinical research indicating that combining amsulostat with a hypomethylating agent may reactivate red blood cell and platelet production. It is assessing whether this approach may reduce dependence on blood transfusions and lower the risk of progression to acute myeloid leukaemia.

AZALOX represents a potential indication expansion for amsulostat beyond its FDA-supported development pathway in myelofibrosis. In parallel, the Australasian Leukaemia & Lymphoma Group is leading the Australian MDS05/D3 MESSAGE study evaluating amsulostat in combination with the oral hypomethylating agent ASTX727 in patients with transfusion-dependent low and intermediate-risk MDS. Recruitment for the initial dose-escalation cohort of the MESSAGE study is ongoing, although enrolment has progressed more slowly than anticipated. Preliminary results are currently anticipated during the first half of calendar 2027.

SNT-4728

Preliminary Phase 2 Results Show Reduced Brain Inflammation
Syntara reported preliminary results from its randomised, double-blind, placebo-controlled Phase 2 study of SNT-4728 in participants with isolated REM Sleep Behaviour Disorder (iRBD), a condition associated with a high risk of progression to Parkinson's disease and related neurodegenerative disorders.

The multi-centre study enrolled 41 participants, randomised 3:1 to receive SNT-4728 or placebo over 12 weeks. The study evaluated safety and exploratory

efficacy, including changes in symptoms and brain inflammation measured using translocator protein positron emission tomography (TSPO PET) imaging.

Preliminary analysis demonstrated a statistically significant unilateral reduction in inflammation within the putamen (p=0.0145), with 20 of the 30 participants receiving SNT-4728 recording a reduction from baseline. The putamen is a key region involved in the motor symptoms associated with Parkinson's disease, including bradykinesia, rigidity and tremor.

No statistically significant changes in inflammation were detected in the other predefined regions of interest, comprising the substantia nigra, caudate and occipital cortex. Broader imaging analyses identified additional areas of significantly reduced TSPO signalling, including regions within the temporal lobe. SNT-4728 was safe and well tolerated, with no treatment-related serious adverse events reported. All adverse events reported across the treatment arms were mild or moderate in severity. The once-daily 15 mg dose was selected based on earlier clinical studies demonstrating that the compound crosses the blood-brain barrier and was expected to provide strong engagement of its two enzyme targets, SSAO and MAO-B.

The enrolled population showed characteristics associated with an elevated risk of progression to Parkinson's disease and related disorders, including misfolded alpha-synuclein in the cerebrospinal fluid of 95% of participants. Based on the emerging evidence of biological activity, Syntara filed a new provisional patent application covering SNT-4728 as a neuro-targeted anti-inflammatory therapy in iRBD.

Additional Results Show Improvement in Clinician-Assessed Motor Signs
Subsequent to the end of the period, Syntara announced additional clinical results from the Phase 2 study, complementing the reduction in neuroinflammation reported in July.

The completed clinical dataset showed a progressive difference between the treatment and placebo groups in clinician-assessed motor signs at Weeks 12 and 24, measured using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS Part III). The difference was statistically significant at Week 24, 12 weeks after treatment ceased (p=0.021).

Participants receiving SNT-4728 showed a slight improvement in motor scores following the 12-week treatment period, while participants receiving placebo showed worsening scores. At Week 24, participants previously treated with SNT-4728 showed further improvement, while the placebo group continued to deteriorate. MDS-UPDRS Part III assesses motor features including bradykinesia, rigidity, tremor, gait and postural stability.

The clinician-assessed findings were directionally consistent with an exploratory motor composite score derived from participant-performed smartphone tasks, although the difference between treatment groups on this measure was not statistically significant. No marked changes over time were observed in other MDS-UPDRS measures or in overall cognitive, quality-of-life and iRBD questionnaire measures.

The study's small size, exploratory design and relatively short treatment period mean that further studies are required to establish clinical benefit and any effect on disease progression. Nevertheless, the combination of biological activity and

improvement in clinician-assessed motor function provides a rationale for further development of SNT-4728 in iRBD and potentially early Parkinson's disease.
The results were selected for presentation by Principal Investigator Professor Simon Lewis at the Clinical Breakthroughs Plenary Session of the International Congress of Parkinson's Disease and Movement Disorders in Seoul, South Korea.
Further analyses of digital endpoints and clinical, biological and imaging biomarkers remain outstanding and are expected to be reported in a future scientific presentation or publication.

The study was supported by funding from Parkinson's Research Ventures, with Principal Investigators Professor Simon Lewis in Sydney and Professor Michele Hu in Oxford.

Skin Scarring Programs

SNT-9465 Phase 1b Study Expanded to 30 Participants

Subsequent to the end of the quarter, Syntara announced an expansion of the Phase 1b study of SNT-9465, its second-generation topical pan-lysyl oxidase (pan-LOX) inhibitor, in participants with hypertrophic scars following sternotomy surgery.

With recruitment of the initial 20-participant cohort nearing completion, Syntara elected to expand the double-blind, placebo-controlled study to 30 participants following encouraging feedback from clinical sites and participant engagement. The expansion is designed to provide a larger safety, tolerability and exploratory activity dataset. The study remains blinded, and the decision to expand recruitment was not based on treatment efficacy data.

The Skin Hospital in Sydney was added as an additional clinical site to support recruitment of the expanded cohort. The study protocol has also been refined to optimise product application and treatment consistency. Top-line results are now expected in Q1 2027.

The study assesses the safety and tolerability of topical SNT-9465 alongside exploratory measures of biological and clinical activity. Each participant receives SNT-9465 and placebo on comparable areas of their scar, allowing treatment-related differences to be assessed within participants while reducing the influence of variation in scar characteristics between participants.

Exploratory SNT-6302 Keloid Scar Study

Also following the end of the quarter, the Company announced preliminary findings from the investigator-initiated SATELLITE study, conducted with the University of Western Australia and the Fiona Wood Foundation, evaluating SNT-6302 in keloid scars.

Six participants had completed the 12-week treatment period and remained in follow-up, with assessments planned for nine months after treatment.
Preliminary findings included an increase in blood-vessel area density at Week 12, directionally consistent with observations in hypertrophic-scar participants in the earlier SOLARIA2 study. No observable differences in Patient and Observer Scar Assessment Scale scores or scar stiffness were identified at Week 12.
Eight participants discontinued treatment due to mild, reversible local skin reactions, mainly erythema and pruritus, consistent with the tolerability

observations in SOLARIA2. These findings further support the rationale for progressing SNT-9465.

Interpretation of the preliminary findings is limited by the exploratory study design, the small number of participants completing treatment and differences in baseline scar characteristics. Further end-of-treatment and follow-up data remain outstanding. Syntara and Professor Fiona Wood will review the complete dataset to consider how it may inform a potential follow-on study in keloid scars.

CORPORATE

A$4.7 million R&D Tax Incentive Received

During the quarter, Syntara received a A$4.7 million research and development tax incentive refund for eligible activities undertaken during the 2026 financial year.

The refund provides non-dilutive funding to support the Company's development programs while maintaining financial flexibility.

FINANCIAL

Financial performance

At the end of the September 2026 quarter, Syntara had a closing cash balance of $14.1 million, compared to $13.5 million at 30 June 2026. The net cash inflow of $0.6 million largely driven by the receipt of the FY26 Research and Development Tax Incentive (RDTI) of $4.7 million in the quarter.

The net cash inflows in operating activities during the quarter was $0.6 million (included the receipt of $4.7 million of receipt of the FY26 RDTI, compared with $3.6 million for the previous quarter to 30 June 2026).

R&D ($2.0 million) and staff costs ($1.7 million) totalling $3.7 million represented 89% of the Company's total net operating cash outflows. Of the $2.0 million direct R&D expenditure the majority was represented by expenditure on the Company's ongoing major clinical programs:

- the Phase 2a trial in MF;
- the Phase 1a/b trial for hypertrophic scars; and
- the iRBD trial, where the majority of the costs of this trial are funded by a grant from Parkinson's UK.

Amounts owed from the sale of the mannitol respiratory business

Syntara sold its mannitol respiratory business unit (MBU) in the fourth quarter of 2023 to Arna Pharma Pty Ltd (Arna Pharma).

As previously disclosed, Arna Pharma and Syntara were in a dispute with respect to amounts owing by each party. While the parties had made some progress in reconciling amounts claimed and certain payments had been received from Arna Pharma, Arna Pharma entered voluntary administration in September 2026 and subsequently entered liquidation in October 2026. The liquidator's initial

guidance is that unsecured creditors, such as Syntara, are unlikely to receive any distribution in the liquidation. While recovery from the liquidation is unlikely, Syntara continues to assess its options in relation to recovery of the outstanding balance. Syntara anticipates that the liquidator may seek to pursue certain claims previously raised by Arna Pharma. While Syntara views these claims as unsubstantiated, addressing them will result in associated legal costs and uncertainty.

Factoring in amounts already paid by Arna Pharma (~$6.1 million) and various offsets from expenses incurred by Syntara, the amounts currently claimed by Syntara at 30 September 2026 have been substantially reduced and now total ~$0.6 million. Given the prior uncertainty regarding recoverability, the receivable had been fully impaired in prior reporting periods. Accordingly, the liquidation is not expected to have a material impact on Syntara's profit and loss.

Syntara's research laboratories and corporate offices are located at the Frenchs Forest facility which had been under a sublease arrangement with Arna Pharma. Following the appointment of a liquidator to Arna Pharma, the head lease and sublease have been terminated. Syntara continues to occupy the premises and is engaging with the property owner regarding arrangements that would enable Syntara to continue occupying the premises for the near term. Despite these discussions, it is likely that Syntara will need to relocate its operations, which will incur future relocation and transition costs and may potentially cause some disruption to Syntara's early stage research programs.

Payments to Related Entities

In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of Appendix 4C incorporates directors' fees, salaries and superannuation. Payments made for the quarter total $238,000 and relate to payments to the CEO/Managing Director in accordance with employment contracts, as well as payments to the Non-Executive Directors.

#ENDS#

About Syntara

Syntara Limited (ABN: 75 082 811 630) is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.

Lead candidate amsulostat (also known as SNT-5505 and previously as PXS-5505) is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. Amsulostat has been granted Fast Track Designation, having already achieved FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for development in myelofibrosis. Amsulostat has now completed a Phase 2a trial in myelofibrosis in which it was dosed as monotherapy and in combination with a JAK inhibitor. Two Phase 1c/2 studies with amsulostat in patients with a blood cancer called myelodysplastic syndrome has been initiated.

Syntara is also advancing topical pan-LOX inhibitors with SNT-9465 in a Phase 1a/b study of hypertrophic scars and continuing the ongoing collaboration with Professor Fiona Wood and the University of Western Australia studying SNT-6302 in keloid scars. SNT-4728 is being studied in collaboration with Parkinson's UK as a best-in-class SSAO/MAO-B inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson's by reducing neuroinflammation.

Other Syntara drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, MASH, pulmonary fibrosis and cardiac fibrosis.

Syntara developed two respiratory products available in world markets (Bronchitol® for cystic fibrosis and Aridol®- a lung function test), which it sold in October 2023.

Syntara is listed on the Australian Securities Exchange, code SNT. The company's management and scientific discovery team are based in Sydney, Australia. www.syntaraTX.com.au.

Forward-Looking Statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.

SOURCE:
Syntara Limited (ASX: SNT),
Sydney, Australia
(ABN: 75 082 811 630)

AUTHORISED FOR RELEASE TO ASX BY:
Syntara Limited Disclosure Committee.

CONTACT:

Syntara investor / media relations:
Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

JOIN THE SYNTARA MAILING LIST HERE

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

SYNTARA LIMITED

75 082 811 630	**Quarter ended ("current quarter")** 30 September 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	48	48
1.2	Payments for		
	(a) research and development	(1,989)	(1,989)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs	(1,787)	(1,787)
	(f) administration and corporate costs	(597)	(597)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	46	46
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	4,753	4,753
1.8	Other (provide details if material)	175	175
1.9	**Net cash from / (used in) operating activities**	**649**	**649**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
2.2	Proceeds from disposal of:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	-	-
	(j) investments	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(157)	(157)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (repayment of lease liability)	-	-
3.10	**Net cash from / (used in) financing activities**	**(157)**	**(157)**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	13,562	13,562
4.2	Net cash from / (used in) operating activities (item 1.9 above)	649	649
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(157)	(157)
4.5	Effect of movement in exchange rates on cash held	6	6
4.6	**Cash and cash equivalents at end of period**	**14,060**	**14,060**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	1,857	1,200
5.2	Call deposits	12,203	12,362
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**14,060**	**13,562**

6.	**Payments to related parties of the entity and their associates**	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	238
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

The amount at 6.1 includes Director fees and salary (including short term incentives and superannuation) for the CEO and Managing Director and Non-Executive Directors.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	**-**	**-**

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

N/A

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	649
8.2	Cash and cash equivalents at quarter end (item 4.6)	14,060
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	14,060
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**N/A**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

30 October 2026

Date: .....

The Board of Directors

Authorised by: .....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.